

Arkansas Medicaid Prescription Drug Program Hepatitis C Virus (HCV) Medication Therapy Request Sheet

Fax completed form and required documentation to the CareSource PASSE Pharmacy Program.

Fax: 1-866-930-0019 For questions call Provider Services: 1-833-230-2100

Preferred: ZEPATIER (elbasvir and grazoprevir); EPCLUSA (velpatasvir and sofosbuvir); MAVYRET (glecaprevir and pibrentasvir tablet)

ARKANSAS PROVIDER NPI:	BENEFICIARY MEDICAID ID NUMBER:
Prescriber Name:	Patient Name:
Address:	Address:
City: _____ State: _____ Zip: _____	City: _____ State: _____ Zip: _____
Phone () _____	Patient's date of birth: / /
FAX () _____	

Adherence with prescribed therapy is a condition for payment of continuation therapy for up to the allowed timeframe for each HCV genotype. The recipient's Medicaid drug history will be reviewed prior to approval.

Supporting documentation must be included with PA request. Submitting documentation of the required lab tests for the drug PA request does not constitute Medicaid approval or payment guarantee for any of the lab tests performed.

HCV POPULATION (CHOOSE ONE THAT APPLIES)	DRUG AND LENGTH OF THERAPY
GT-1a; F3 or F4, CPS-A, TN or TE-PR, + RAV Resistance	ZEPATIER + RBV X 16 WKS
GT-1a; F3 or F4, CPS-A, TN or TE-PR, - RAV Resistance	ZEPATIER X 12 WKS
GT-1a; F3 or F4, CPS-A, TE-PR+PI, - RAV Resistance	ZEPATIER + RBV X 12 WKS
GT-1b; F3 or F4, CPS-A, TN or TE-PR	ZEPATIER X 12 WKS
GT-1b; F3 or F4, CPS-A, TE-PR+PI	ZEPATIER + RBV X 12 WKS
GT-4; F3 or F4, CPS-A, TN	ZEPATIER X 12 WKS
GT-4; F3 or F4, CPS-A, TE-PR	ZEPATIER + RBV X 16 WKS
GT-1, 2, 3, 4, 5, or 6; TN, or TE-PR, or TE-PR+PI, F3 or F4, CPS-A	EPCLUSA X 12 WKS
GT-1, 2, 3, 4, 5, or 6; TN, or TE-PR, or TE-PR+PI, F4, CPS-B or CPS-C	EPCLUSA + RBV X 12 WKS
GT-1, 2, 3, 4, 5, or 6; TN, F3 or F4, CPS-A	MAVYRET X 8 WKS
GT-1, 2, 4, 5, or 6; TE-PRS ³ , F3, No Cirrhosis	MAVYRET X 8 WKS
GT-1, 2, 4, 5, or 6; TE-PRS ³ , F4, CPS-A	MAVYRET X 12 WKS
GT-1; TE-NS3/4A-PI ² , F3 or F4, CPS-A	MAVYRET X 12 WKS
GT-1; TE-NS5A ¹ , F3 or F4, CPS-A	MAVYRET X 16 WKS
GT-3; TE-PRS ³ , F3 or F4, CPS-A	MAVYRET X 16 WKS

GT = GENOTYPE

FOR PURPOSES OF THE PA REQUEST: Advanced fibrosis = Metavir F3; Cirrhosis = Metavir F4;

Compensated cirrhosis = CPS-A; DECOMPENSATED = Metavir F4 or F3 and CPS-B or CPS-C

TN = TREATMENT NAÏVE

TE = TREATMENT EXPERIENCED;

TREATMENT EXPERIENCED APPROVALS MUST MEET FDA-APPROVED INDICATIONS AND CLINICAL TRIAL DATA FOR PREVIOUS THERAPY

TE-PR = TREATMENT EXPERIENCED with pegylated interferon + ribavirin (PegINF+RBV)

TE-PR+PI = TREATMENT EXPERIENCED with PegINF+RBV+PROTEASE INHIBITOR (boceprevir, simeprevir, or telaprevir);

CPS = CHILD PUGH SCORE, CAN BE A, B OR C

RAV = NS5A resistance-associated polymorphisms, either negative (-) or positive (+) for resistance variants.

TE-NS5A¹ = prior regimens containing ledipasvir and sofosbuvir or daclatasvir with PegINF+RBV without prior treatment with NS3/4A

TE-NS3/4A² = regimens contained simeprevir and sofosbuvir, or simeprevir, boceprevir, or telaprevir with PegINF+RBV without prior treatment with an NS5A inhibitor

TE-PRS³ = regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor.

1. Diagnosis: ACUTE HEPATITIS C <input type="checkbox"/>	CHRONIC HEPATITIS C <input type="checkbox"/>	OTHER <input type="checkbox"/>	Define Other:
2. This request is for: TREATMENT NAÏVE <input type="checkbox"/> TREATMENT EXPERIENCED <input type="checkbox"/>			
3. If treatment experienced, list all previous drug regimen(s):			
4. This request is for: NEW REQUEST <input type="checkbox"/> CONTINUATION REQUEST <input type="checkbox"/>			

5. Does patient have HIV/HCV or HBV/HCV co-infection? YES NO HIV HBV

If YES, treatment of HIC/HCV-co-infected patients requires continued awareness and attention to the complex drug interactions that can occur between DAAs and antiretroviral medications. Please refer to the AASLD HCV guidelines or the DHHS HIV treatment guidelines.⁴

6. What is patient's HCV genotype (GT)? 1a 1b 2 3 4 5 6 (circle one)

7. If patient is GT-1a, submit lab results from NS5A resistance-associated polymorphism testing.

****This information is mandatory for all GT-1a requests****

8. Submit current documentation for all liver function lab test results, such as Platelets, INR, ALT, AST, etc.

9. What is the Metavir Score? 0 1 2 3 4 (circle one)

10. Does the patient have a diagnosis of cirrhosis? YES NO

11. If YES for cirrhosis, has a liver biopsy been performed? YES NO IF YES, INCLUDE COPY OF BIOPSY RESULTS

12. If patient has cirrhosis and liver biopsy has *not* been performed, submit definitive documentation from 2 modalities to confirm cirrhosis:

1. Submit results from a patented serum panel (such as HCV FibroSURE™, ActiTest™, ELF or simplified ELF index) AND
2. Submit results from an imaging modality (such as FibroSCAN® or Magnetic Resonance Elastography (MRE))

13. For all Genotypes, provide the patient's Child-Pugh or Child-Turcotte-Pugh score (CPS-A, B, or C): _____

14. Provide the patient's Model for End-State Liver Disease (MELD) score: _____

15. Does the patient have any extrahepatic disease manifestations caused by HCV? YES NO

If YES, list: _____

16. If applicable, has the patient been abstinent from IV drug use or alcohol abuse for \geq 6 months? YES NO

If NO, is patient currently enrolled in drug rehabilitation program? YES NO

17. Does the patient have a history of any of the following? Please mark all that apply.

- | | |
|---|---|
| <input type="checkbox"/> Anemia | <input type="checkbox"/> Mental illness, including bipolar, mood swings, mania, schizophrenia |
| <input type="checkbox"/> Unstable CVD | <input type="checkbox"/> Autoimmune disease |
| <input type="checkbox"/> Kidney Transplant | <input type="checkbox"/> Depression, irritability, suicidal ideation |
| <input type="checkbox"/> Pregnancy ⁵ | <input type="checkbox"/> Untreated hyperthyroidism |
| <input type="checkbox"/> Thrombocytopenia | <input type="checkbox"/> Chronic Kidney Disease (Stage 3-Stage 5D) |

18. Has on the above required supporting documentation been included with this request? YES NO

The above format is to assist the prescriber in providing medical documentation that Arkansas Medicaid requires to review this request.

Prescriber Signature: _____ DATE: _____

Prescriber's original signature required; copied, stamped, or e-signature not allowed for a PA request

All PA requests must be from a hepatologist, gastroenterologist, infectious disease specialist, or a prescriber working under the direct supervision of one of these specialty physicians

⁴American Association for the Study of Liver Diseases (AASLD). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Unique patient populations: patients with HIV/HCV coinfection. Retrieved 11/12/15 from <http://www.hcvguidelines.org/full-report-view>

⁵ Black box warning. Ribavirin causes significant teratogenic effects. Copegus® (ribavirin) package insert. Roche Laboratories, Inc. Revised April 2009. Retrieved May 20, 2009, from <http://www.rocheusa.com/products/copegus/pi.pdf>.